NCT06170216已完成不适用
A Single-center, Non-interventionary Clinical Study Evaluating the Efficacy and Safety of Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 206
- 试验地点
- 2
- 主要终点
- ORR
研究概览
简要总结
Describe the application status of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), observe the therapeutic efficacy and safety of the treatment modalities.
详细描述
Evaluated the efficacy and safety of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL)
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old
- •Initial or first recurrent iNHL confirmed by histopathology, including FL (1-3a), MZL, MCL;
- •Sign an informed consent form;
- •Researchers evaluate patients who can benefit from receiving immunochemotherapy.
排除标准
- •There are contraindications to any medication in the treatment plan;
- •Pregnant or lactating women or male and female participants of childbearing age did not take contraceptive measures during the trial period and within 30 days after the last medication;
- •Researchers believe that patients who are not suitable for enrollment.
研究组 & 干预措施
small B-cell non-Hodgkin lymphoma
Different immunochemotherapies in small B-cell non-Hodgkin lymphoma
干预措施: immunochemotherapies (Drug)
结局指标
主要结局
ORR
时间窗: up to 6 months
the ratio of numbers of patients with complete response and partial response to all the participants receiving treatment
次要结局
- 2-year event-free survival (EFS)(From date of patients sign informed consent until the date of first documented event, progression or date of death from any cause, whichever came first, assessed up to 2 years)
- 2-year progression-free survival (PFS)(From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years)
- overall survival(From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 2 years)
- Hematology and non hematology toxicity(Throughout the treatment period，up to 6 months)
研究者
Yizhen Liu
Clinical Professor
Fudan University
研究点 (2)
Loading locations...
相似试验
招募中
3 期
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedDiffuse Large B-cell LymphomaB-cell NonHodgkin LymphomaMantle Cell LymphomaNCT05097443Shandong Provincial Hospital130
已完成
2 期
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT00547534University of Rochester31
尚未招募
2 期
Comparing Use of B-cell depletion therapy to Immunoglobulin in Chronic inflammatory demyelinating polyneuropathy (CUBIC) clinical trial.Chronic inflammatory demyelinating polyneuropathy (CIDP).Inflammatory and Immune System - Autoimmune diseasesNeurological - Other neurological disordersACTRN12623001336673Western Sydney Local Health District35
Unknown
早期 1 期
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic MalignanciesCD5+ Relapsed/Refractory Hematopoietic MalignanciesChronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Peripheral T-cell Lymphomas (PTCL)NCT04767308Huazhong University of Science and Technology18
已完成
2 期
A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus CarriersNon-Hodgkin's LymphomaNCT00262210National Health Research Institutes, Taiwan50